Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mindray Bio-Medical Re-Files for Hong Kong Listing After Initial Application Expiration

Fineline Cube May 12, 2026
Company Deals

Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer

Fineline Cube May 12, 2026
Company Deals

China Medical System Secures Exclusive China Rights to Pharmacosmos’ MonoFer and CosmoFer IV Iron Therapies

Fineline Cube May 12, 2026
Company Deals

Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization

Fineline Cube May 12, 2026
Company Deals

Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market

Fineline Cube May 12, 2026
Policy / Regulatory

NMPA Releases 105th Batch of Generic Drug Reference Standards, Adding 37 New Specifications

Fineline Cube May 12, 2026
Company Drug

Merus’ Bizengri Becomes First FDA-Approved Therapy for NRG1 Fusion-Positive Cholangiocarcinoma

Fineline Cube May 12, 2026
Company Drug

Zai Lab Secures FDA Fast Track Designation for DLL3-Targeting ADC Zocilurtatug Pelitecan in Extrapulmonary NEC

Fineline Cube May 12, 2026
Company Medical Device

Kehua Bioengineering Gains NMPA Approval for Gene Polymorphism Detection Kits

Fineline Cube Jan 22, 2025

China-based Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022) has announced receiving marketing approvals from the...

Company Drug

Humanwell’s HWH340 Receives Clinical Approval for Prostate Cancer Treatment

Fineline Cube Jan 22, 2025

Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that its Class 1 chemical drug...

Company Deals

Sichuan Biokin Re-submits IPO Application to Hong Kong Stock Exchange

Fineline Cube Jan 22, 2025

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has resubmitted its application...

Company Medical Device

Acotec’s Vericor-S2 Coronary Microcatheter Approved by NMPA

Fineline Cube Jan 22, 2025

Acotec Scientific Holdings Ltd (HKG: 6669) has announced that its Vericor-S2 coronary microcatheter has received...

Company Deals

Lepu Biopharma Licenses Potential Best-in-Class ADC MRG007 to ArriVent

Fineline Cube Jan 22, 2025

Lepu Biopharma Co., Ltd (HKG: 2157) has announced an exclusive licensing agreement with ArriVent BioPharma,...

Policy / Regulatory

Trump Signs Executive Order to Withdraw from WHO, Drawing Criticism

Fineline Cube Jan 21, 2025

President Donald Trump has signed an executive order indicating the withdrawal of the United States...

Hospital

Douyin Gains Approval to Establish Hospital in Beijing’s Zhongguancun

Fineline Cube Jan 21, 2025

The Beijing Municipal Health Commission has approved Douyin, the Chinese short-form video hosting service owned...

Company Medical Device

NMPA Approves Synaptic Medical’s Cryoablation Device and Gene Methylation Detection Kit

Fineline Cube Jan 21, 2025

China’s National Medical Products Administration (NMPA) has granted marketing approval for two new medical devices:...

Company Drug

Huadong Medicine’s MediBeacon TGFR System Receives FDA Marketing Clearance

Fineline Cube Jan 21, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing clearance from the US...

Company Drug

MediLink’s YL201 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma

Fineline Cube Jan 21, 2025

Suzhou-based biotech MediLink Therapeutics (Suzhou) Co., Ltd has announced receiving another breakthrough therapy designation (BTD)...

Company Drug

Jiangsu Lianhuan Completes Enrollment for Phase III Study of LH-1801 in Type 2 Diabetes

Fineline Cube Jan 21, 2025

China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) has announced the completion of subject enrollment...

Company Drug

Arrowhead’s Plozasiran Accepted for FDA Review in Familial Chylomicronemia Syndrome

Fineline Cube Jan 21, 2025

US-based Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced that the New Drug Application (NDA) for...

Company Deals

Keymed and InnoCare Announce Licensing Deal for CD20xCD3 Bispecific Antibody with Prolium

Fineline Cube Jan 21, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) and InnoCare Pharma (HKG: 9969, SHA: 688428) have jointly...

Company Drug

GSK’s Jemperli Approved for First-Line Endometrial Cancer Treatment in EU

Fineline Cube Jan 21, 2025

UK-based GSK plc (NYSE: GSK, LON: GSK) has announced receiving approval from the European Commission...

Company Drug

Kelun-Biotech’s Tagitanlimab Receives NMPA Clearance for Nasopharyngeal Carcinoma

Fineline Cube Jan 21, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving another clearance from the...

Company Deals

Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets

Fineline Cube Jan 21, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced a licensing agreement...

Company Drug

CARsgen Therapeutics Initiates Trial for Universal CAR-T Therapy KJ-C2320 in AML

Fineline Cube Jan 21, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the first subject dosing in an...

Company Deals

Danaher Partners with Huashan Hospital to Develop Alzheimer’s Diagnostic Solutions

Fineline Cube Jan 21, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced a partnership between...

Company Drug

Chongqing Genrix’s Xeligekimab Approved for Ankylosing Spondylitis by NMPA

Fineline Cube Jan 21, 2025

China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) has announced receiving approval from the...

Company Deals

Takeda to Establish China Innovation Center in Chengdu, Focusing on Digital Health

Fineline Cube Jan 21, 2025

Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has announced plans to establish the Takeda China Innovation...

Posts pagination

1 … 221 222 223 … 664

Recent updates

  • Merus’ Bizengri Becomes First FDA-Approved Therapy for NRG1 Fusion-Positive Cholangiocarcinoma
  • Zai Lab Secures FDA Fast Track Designation for DLL3-Targeting ADC Zocilurtatug Pelitecan in Extrapulmonary NEC
  • Mindray Bio-Medical Re-Files for Hong Kong Listing After Initial Application Expiration
  • Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention
  • Haisco Pharmaceutical’s Sishujing Seeks Postoperative Pain Indication, Expanding Peripheral Kappa Agonist Franchise
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Merus’ Bizengri Becomes First FDA-Approved Therapy for NRG1 Fusion-Positive Cholangiocarcinoma

Company Drug

Zai Lab Secures FDA Fast Track Designation for DLL3-Targeting ADC Zocilurtatug Pelitecan in Extrapulmonary NEC

Company Deals

Mindray Bio-Medical Re-Files for Hong Kong Listing After Initial Application Expiration

Company Drug

Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.